MONDOMED
ActiveSummary
MONDOMED has been active since 1993 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.5m and a net result of €57,308. Equity remains stable across the filed fiscal years (±2.3% per year). Its solvency ranks better than 61% of 69 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
What they do
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21209NACE 24422
1 site
How big
€4.6mtotal assets 2025
- Equity
- €2.5m
- Profit
- €57,308
Staff (FTE) -100%: other schema
Who decides
- Parent
- PMS MEDICAL · 99.64%
Accounts filed 25 d late0 of 3 deeds read
Why 72- Higher-failure-rate sector+ Long track record+ Annual accounts: healthy financial profile+ Lower-risk legal formFiled after the deadlineShow the evidence
Checked score
Score 2025
Axes · tick = 2024
Profitability70▼-1
Solvency78▼-9
Growth35=
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €170,000 at 30 days acceptable
Liquidity tight (current ratio 1.29 against 1.34 in 2024; short-term debt: 32.4% and cash: 0.2% of total assets), and 46.5% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
53.5%
Return on assets
1.2%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 25-08-2026, 25 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
25 d late
2024
42 d late
2023
34 d early
2022
6 d early
2021
78 d late
2020
32 d early
2019
35 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 5 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 25 August (4 of the last 5 filed years within 53 days of that day).
Companies Code · seven monthsPosition in the running window
01-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · full…
- Annual accounts filedfiscal year 2024 · abbreviated…
- Annual accounts filedfiscal year 2023 · abbreviated…
Financials
Fiscal year 2025Total assets €4.6mProfit €57,308Solvency 53.5%Liquidity 1.29
Turnover
€2.6m▼ 23.2%
2018 - 2019
Net result
€57,308▼ 30.4%
2018 - 2025
Equity
€2.5m▲ 2.4%
2018 - 2025
Staff (FTE)
0▼ 100%
2018 - 2025
Financials · fiscal year 2025, full schema
Trend over the years
Trend over the years
In euros
In per cent
Ratio
In full-time equivalents (FTE)
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
In full-time equivalents (FTE)
No line ticked in this group.
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Turnover
Operating result€0.01m▼ 78.2%€0.1m▲ 723%€0.07m▼ 37.6%€0.1m▲ 100%€0.1m▼ 6.4%
Net result€0.07mwithin the sector's middle half▲ 104%€0.06mwithin the sector's middle half▼ 12.5%€0.02mwithin the sector's middle half▼ 71.3%€0.08mwithin the sector's middle half▲ 359%€0.06mwithin the sector's middle half▼ 30.4%
EBIT margin
Equity€2.3mabove the sector's middle half▲ 3.3%€2.3mabove the sector's middle half▲ 2.8%€2.3mabove the sector's middle half▲ 0.8%€2.4mabove the sector's middle half▲ 3.5%€2.5mwithin the sector's middle half▲ 2.4%
Total assets€3.5mwithin the sector's middle half▲ 8.9%€3.8mabove the sector's middle half▲ 10.8%€3.7mabove the sector's middle half▼ 3.4%€3.9mabove the sector's middle half▲ 6.0%€4.6mwithin the sector's middle half▲ 18.5%
Debt€1.2m▲ 21.4%€1.5m▲ 25.9%€1.4m▼ 10.0%€1.5m▲ 10.4%€2.2m▲ 44.8%
Working capital€0.7mwithin the sector's middle half▼ 6.3%€0.8mabove the sector's middle half▲ 1.8%€0.6mabove the sector's middle half▼ 15.3%€0.4mwithin the sector's middle half▼ 41.5%€0.4mwithin the sector's middle half▲ 17.9%
Solvency65.5%within the sector's middle half▼ 3.6pp60.8%within the sector's middle half▼ 4.7pp63.4%within the sector's middle half▲ 2.7pp61.9%within the sector's middle half▼ 1.5pp53.5%within the sector's middle half▼ 8.4pp
Current ratio2.07within the sector's middle half▼ 0.131.69within the sector's middle half▼ 0.381.62within the sector's middle half▼ 0.071.34within the sector's middle half▼ 0.281.29within the sector's middle half▼ 0.05
Return on assets (ROA)2.1%within the sector's middle half▲ 1.0pp1.6%within the sector's middle half▼ 0.4pp0.5%within the sector's middle half▼ 1.1pp2.1%within the sector's middle half▲ 1.6pp1.2%within the sector's middle half▼ 0.9pp
Staff (FTE)15.2▲ 1.3%18.1above the sector's middle half▲ 19.1%20.2above the sector's middle half▲ 11.6%20.3above the sector's middle half▲ 0.5%0below the sector's middle half▼ 100%
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2025 Staff (FTE) -100% on 2024. The accounts now follow the full schema, last year the abbreviated schema.
Result and balance sheet
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 6% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.6m
Fixed assets
€2.7m ▲ 10.4%
Current assets
€1.9m ▲ 32.1%
Equity and liabilities €4.6m
Equity
€2.5m ▲ 2.4%
Debt
€2.2m ▲ 44.8%
Debt's share of the balance-sheet total rises from 38.1% to 46.5%. Equity and debt are higher.
Key figures and ratios
Key figures and ratios
EBITDA
€449,420▲
2024 · €410,837
Cash flow
€372,841▲
2024 · €350,158
Quick ratio
0.30▼
2024 · 0.54
Debt to equity
0.87▲
2024 · 0.62
ROE
2.3%▼
2024 · 3.4%
Interest coverage
6.88▼
2024 · 7.61
Debt ≤ 1 year
€1.5m▲
2024 · €1.1m
Debt > 1 year
€655,777▲
2024 · €392,321
Income taxes
€12,146▲
2024 · €8,380
Staff costs
€1.3m▲
2024 · €1.2m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 14,732 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 96% are still going.
- Small
- 20 years or older
- solvency 30% or more
- a profit under 5% of the balance sheet
0.2%
went bankrupt
3.5%
stopped otherwise
96%
still going
A further 0.1% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,341 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 14,732 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Filed annual accounts
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €0.001m | €0.03m | €0 | - | - |
| Remuneration, social security and pensions62 | €0.9m | €1.1m | €1.2m | €1.2m | €1.3m | ▲ 14.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.1m | €0.1m | €0.2m | €0.3m | €0.3m | ▲ 17.8% |
| Other operating charges640/8 | €0.03m | €0.03m | €0.05m | €0.05m | €0.06m | ▲ 28.3% |
| Non-recurring operating charges66A | €0 | €0.03m | €0 | - | - | - |
| Gross operating margin9900 | €1.1m | €1.5m | €1.6m | €1.6m | €1.9m | ▲ 13.3% |
| Operating profit (loss)9901 | €0.01m | €0.1m | €0.07m | €0.1m | €0.1m | ▼ 6.4% |
| Financial income75/76B | €0.08m | €0.001m | €0.002m | €0.002m | €0.001m | ▼ 48.9% |
| Recurring financial income75 | €0.08m | €0.001m | €0.002m | €0.002m | €0.001m | ▼ 48.9% |
| Financial charges65/66B | €0.03m | €0.03m | €0.05m | €0.05m | €0.07m | ▲ 21.0% |
| Recurring financial charges65 | €0.03m | €0.03m | €0.05m | €0.05m | €0.07m | ▲ 21.0% |
| Profit (loss) for the period before taxes9903 | €0.07m | €0.09m | €0.02m | €0.09m | €0.07m | ▼ 23.4% |
| Income taxes67/77 | €0.001m | €0.03m | €0.005m | €0.008m | €0.01m | ▲ 44.9% |
| Profit (loss) for the period9904 | €0.07m | €0.06m | €0.02m | €0.08m | €0.06m | ▼ 30.4% |
| Profit (loss) for the period to be appropriated9905 | €0.07m | €0.06m | €0.02m | €0.08m | €0.06m | ▼ 30.4% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €3.5m | €3.8m | €3.7m | €3.9m | €4.6m | ▲ 18.5% |
| Fixed assets21/28 | €2.0m | €2.0m | €2.0m | €2.4m | €2.7m | ▲ 10.4% |
| Intangible fixed assets21 | €0.1m | €0.1m | €0.2m | €0.3m | €0.2m | ▼ 32.7% |
| Tangible fixed assets22/27 | €1.9m | €1.9m | €1.9m | €2.2m | €2.5m | ▲ 15.5% |
| Land and buildings22 | €0.8m | €0.7m | €0.7m | €0.9m | €1.3m | ▲ 38.3% |
| Plant, machinery and equipment23 | €1.1m | €1.1m | €1.1m | €1.2m | €1.2m | ▼ 0.3% |
| Furniture and vehicles24 | €0.05m | €0.06m | €0.04m | €0.05m | €0.05m | ▼ 17.1% |
| Current assets29/58 | €1.4m | €1.8m | €1.7m | €1.5m | €1.9m | ▲ 32.1% |
| Stocks and contracts in progress3 | €0.6m | €0.8m | €0.9m | €0.9m | €1.5m | ▲ 71.4% |
| Stocks30/36 | €0.6m | €0.8m | €0.9m | €0.9m | €1.5m | ▲ 75.3% |
| Contracts in progress37 | €0.003m | - | - | €0.02m | - | - |
| Amounts receivable within one year40/41 | €0.7m | €1.0m | €0.8m | €0.6m | €0.4m | ▼ 27.1% |
| Trade receivables40 | €0.7m | €1.0m | €0.7m | €0.5m | €0.4m | ▼ 26.4% |
| Other amounts receivable41 | €0.03m | €0.03m | €0.06m | €0.08m | €0.05m | ▼ 31.3% |
| Cash at bank and in hand54/58 | €0.01m | €0.002m | €0.003m | €0.001m | €0.009m | ▲ 800% |
| Deferred charges and accrued income490/1 | €0.06m | €0.008m | €0.01m | €0.01m | €0.01m | ▼ 5.2% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €3.5m | €3.8m | €3.7m | €3.9m | €4.6m | ▲ 18.5% |
| Equity10/15 | €2.3m | €2.3m | €2.3m | €2.4m | €2.5m | ▲ 2.4% |
| Contributions10/11 | €0.5m | €0.5m | €0.5m | €0.5m | €0.5m | = |
| Capital10 | €0.5m | €0.5m | €0.5m | €0.5m | €0.5m | = |
| Issued capital100 | €0.5m | €0.5m | €0.5m | €0.5m | €0.5m | = |
| Reserves13 | €1.8m | €1.9m | €1.9m | €2.0m | €2.0m | ▲ 2.9% |
| Non-distributable reserves130/1 | €0.05m | €0.05m | €0.05m | €0.05m | €0.05m | = |
| Legal reserve130 | €0.05m | €0.05m | €0.05m | €0.05m | €0.05m | = |
| Tax-exempt reserves132 | €0.004m | €0.004m | €0.004m | €0.004m | €0.004m | = |
| Distributable reserves133 | €1.8m | €1.8m | €1.8m | €1.9m | €2.0m | ▲ 3.0% |
| Amounts payable17/49 | €1.2m | €1.5m | €1.4m | €1.5m | €2.2m | ▲ 44.8% |
| Amounts payable after more than one year17 | €0.5m | €0.4m | €0.3m | €0.4m | €0.7m | ▲ 67.2% |
| Financial debts170/4 | €0.3m | €0.2m | €0.1m | €0.2m | €0.3m | ▲ 67.8% |
| Other amounts payable178/9 | €0.2m | €0.2m | €0.2m | €0.2m | €0.4m | ▲ 66.7% |
| Amounts payable within one year42/48 | €0.7m | €1.1m | €1.0m | €1.1m | €1.5m | ▲ 36.9% |
| Current portion of amounts payable after more than one year42 | €0.1m | €0.1m | €0.09m | €0.1m | €0.2m | ▲ 47.8% |
| Financial debts43 | €0.3m | €0.6m | €0.6m | €0.5m | €0.7m | ▲ 43.1% |
| Credit institutions430/8 | €0.3m | €0.6m | €0.6m | €0.5m | €0.7m | ▲ 43.1% |
| Trade debts44 | €0.2m | €0.3m | €0.3m | €0.4m | €0.6m | ▲ 30.8% |
| Suppliers440/4 | €0.2m | €0.3m | €0.3m | €0.4m | €0.6m | ▲ 30.8% |
| Taxes, remuneration and social security45 | €0.06m | €0.08m | €0.06m | €0.1m | €0.1m | ▲ 23.2% |
| Taxes450/3 | €0.001m | €460 | €0 | €0.001m | €0.01m | ▲ 985% |
| Remuneration and social security454/9 | €0.06m | €0.08m | €0.06m | €0.1m | €0.1m | ▲ 11.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €71,604 | €62,633 | €17,957 | €82,337 | €57,308 | ▼ 30.4% |
| + Depreciation and write-downs630 | €96,399 | €146,783 | €191,895 | €267,820 | €315,533 | ▲ 17.8% |
| Operating cash flow (approximation) | €168,002 | €209,417 | €209,852 | €350,158 | €372,841 | ▲ 6.5% |
| Investment in fixed assets (approximation) | - | -€105,894 | -€235,329 | -€685,439 | -€569,134 | ▲ 17.0% |
| Change in cash | - | -€10,617 | €444 | -€1,648 | €7,695 | ▲ 567% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Comparable companies
Similar companies · same sector, comparable size
DELAVAL
BE 0427.530.468
Gent · Eq €2.4m
remedent
BE 0474.973.168
Gent · Eq €2.3m
LABORATOIRES LOHMANN & RAUSCHER
BE 0402.437.261
Liège · Eq €2.0m
Phoenix Biosciences
BE 1027.640.071
Nivelles · Eq €3.7m
MEDI - LINE
BE 0452.084.633
Liège · Eq €3.8m
Of 97 companies in this sector we hold annual accounts for 74. 41 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Board & ownership
Parent PMS MEDICAL · 99.64%
Directors
Directors
No directors read yet: 0 of 3 Gazette acts processed. See the function holders in the CBE →
Structure & network
Owners and holdings
2 ownersChain of control
- PMS MEDICAL
- MONDOMED
Highest known parent: PMS MEDICAL. The sources do not say who stands above it.
Owners 2
-
99.64%
- Pasquale Cimminonatural personSourceown accounts 20211%
Holdings 0
The accounts to 31-12-2021 list no holdings, and no other source names one.
According to the 2021 annual accounts of MONDOMED and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No directors read yet: 0 of 3 Gazette acts processed.
Timeline
11 eventsLatest 25-08-2026Next filing 31-07-2027
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
25-08
NBB filing
Annual accounts filed
fiscal year 2025 · full schema · 25 days late
2025
11-09
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 42 days late
2024
27-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
25-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
17-10
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 78 days late
2021
29-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
26-06
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
31-12
Financial
Weakest financial yearnet €12,536 ▼89.8%
Net result drops to €12,536, the lowest in the series; recovery starts the following year.
20-05
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
25-05
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
22-05
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Support & recognitions
1 funding sourceFlanders €53,904
Flemish government
€53,904
awarded · 2022 - 2025
Subsidies and aid
Flemish government
2022 to 2025 · 5 entries · €53,904 awarded · €4,007 paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 2 | €50,563 | €1,390 |
| 2024 | 1 | €1,244 | €779 |
| 2023 | 1 | €1,239 | €980 |
| 2022 | 1 | €858 | €858 |
Company details
Public limited company · founded 14-04-1993Year ends 31-12Peppol reachable1 site
Register details
Identification
Legal formPublic limited company
Founded14-04-1993
Fiscal year end31-12
Activities, NACEBEL 2025
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
32500Manufacture of medical and dental instruments and supplies
Contact
E-invoicing
Reachable via Peppol
Peppol ID
0208:0449866303
Also
9925:BE0449866303
Registered
09-02-2026
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 1 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Sites & property
Location & real-estate footprint
Registered office, Hamont-Achel · 1 establishment unit since 1993
Ground area
5,709 m²
Building footprint
3,386 m²
Volume, LiDAR
21,786 m³
Parcel 72012D0514/00H002, Flanders · tallest building 7.6 m, ±2 floors. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
Middenweg 20, 3930 Hamont-Achel
since 1993unit no. 2.061.802.702
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 72012D0514/00H002 | Flanders | 5,709 m² | 1 · 3,386 m² | 7.6 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.